Skip to main content
Equibles
ADMA logo

ADMA · Adma Biologics, Inc. · Webcasts, Transcripts & Audio

Track ADMA — free

Use ADMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.16 +0.05 (+0.49%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.20B
Shares
223.98M
Volume · Oct 5 3.51M Avg daily vol (3M) 2.63M

Adma Biologics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Adma Biologics, Inc. (ADMA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲98.7% $41.09M −$14.90M '22 Q3 22-11-09 ▲89.4% $49.98M −$12.23M '22 Q4 23-03-23 ▲95.6% $56.91M −$6.79M '23 Q1 23-05-10 ▲77.3% $60.12M −$6.37M '23 Q2 23-08-09 ▲63.7% $67.28M $2.56M '23 Q3 23-11-08 ▲47.9% $73.90M −$17.64M '23 Q4 24-01-08 ▲43.9% $81.88M $17.81M '24 Q1 24-05-09 ▲78.3% $107.19M $32.06M '24 Q2 24-08-08 ▲78.1% $119.84M $35.91M '24 Q3 24-11-07 ▲59.1% $117.55M $111.90M '24 Q4 25-03-03 ▲40.2% $114.80M $26.90M '25 Q1 25-05-07 ▲13.8% $121.98M $34.22M '25 Q2 25-08-06 ▲12% $134.22M $36.43M '25 Q3 25-11-05 ▲18.4% $139.16M $49.38M '25 Q4 26-02-25 ▼0.3% $114.49M $45.33M '26 Q1 26-05-06 LATEST ▲2% $124.39M $37.82M '26 Q2 26-08-05
Earnings call
FY26 · Q2
2026-08-05
Adma Biologics, Inc. (ADMA) Q2 2026 Earnings Call
Revenue
$124.39M
▲ 2% YoY
Diluted EPS
$0.16
▲ 14.3% YoY
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Adma Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
Positive tone Ascentive demand growth Pediatric label expansion Vivigam competitive pressure
Revenue
$114.49M
▼ 0.3% YoY
Diluted EPS
$0.19
▲ 72.7% YoY
Gross margin
70.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Adma Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
Confident tone Financial results and profitability Ascentive product growth and demand Yield-enhanced manufacturing
Revenue
$139.16M*
▲ 18.4% YoY
Gross margin
63.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Adma Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript
Confident tone ASCENIV growth and prescriber adoption Financial performance and profitability Capital deployment and guidance
Revenue
$134.22M
▲ 12% YoY
Diluted EPS
$0.15
▲ 0% YoY
Gross margin
56.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Adma Biologics, Inc. (ADMA) Q2 2025 Earnings Call Transcript
Confident tone Revenue Growth & Financial Performance Yield Enhancement / Manufacturing Efficiency Facility Expansion & Capacity Planning
Revenue
$121.98M
▲ 13.8% YoY
Diluted EPS
$0.14
▲ 7.7% YoY
Gross margin
55.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Adma Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript
Confident tone Revenue Growth and Guidance ASCENIV Franchise and Durability Yield Enhancement Production Process
Revenue
$114.80M
▲ 40.2% YoY
Diluted EPS
$0.11
▲ 37.5% YoY
Gross margin
53.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Adma Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript
Confident tone Revenue and earnings momentum ASCENIV product growth and market penetration Enhanced yield production process (regulatory)
Revenue
$117.55M*
▲ 59.1% YoY
Gross margin
53.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Adma Biologics, Inc. (ADMA) Q3 2024 Earnings Call Transcript
Confident tone ASCENIV Commercial Momentum Yield Enhancement Initiative Revenue and Earnings Growth
Revenue
$119.84M
▲ 78.1% YoY
Diluted EPS
$0.15
▲ 1400% YoY
Gross margin
49.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Adma Biologics, Inc. (ADMA) Q2 2024 Earnings Call Transcript
Confident tone ASCENIV demand and penetration Raised financial guidance Revenue growth and milestone
Revenue
$107.19M
▲ 78.3% YoY
Diluted EPS
$0.13
Gross margin
53.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Adma Biologics, Inc. (ADMA) Q1 2024 Earnings Call Transcript
Confident tone Asceniv commercial momentum Post-2025 outlook uncertainty Revenue growth and outperformance
Revenue
$81.88M
▲ 43.9% YoY
Diluted EPS
$0.08
Gross margin
47.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Adma Biologics, Inc. (ADMA) Q4 2023 Earnings Call Transcript
Confident tone Forward Guidance / Outlook ASCENIV Product Performance Revenue and Earnings Growth
Revenue
$73.90M*
▲ 47.9% YoY
Gross margin
42.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Adma Biologics, Inc. (ADMA) Q3 2023 Earnings Call Transcript
Revenue
$67.28M
▲ 63.7% YoY
Diluted EPS
$0.01
Gross margin
36.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Adma Biologics, Inc. (ADMA) Q2 2023 Earnings Call Transcript
Revenue
$60.12M
▲ 77.3% YoY
Diluted EPS
$-0.03
Gross margin
27.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Adma Biologics, Inc. (ADMA) Q1 2023 Earnings Call Transcript
Revenue
$56.91M
▲ 95.6% YoY
Diluted EPS
$-0.03
Gross margin
29.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Adma Biologics, Inc. (ADMA) Q4 2022 Earnings Call Transcript
Revenue
$49.98M*
▲ 89.4% YoY
Gross margin
28.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Adma Biologics, Inc. (ADMA) Q3 2022 Earnings Call Transcript
Revenue
$41.09M
▲ 98.7% YoY
Diluted EPS
$-0.08
Gross margin
23.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Adma Biologics, Inc. (ADMA) Q2 2022 Earnings Call Transcript
Revenue
$33.91M
▲ 90.2% YoY
Diluted EPS
$-0.07
Gross margin
22.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Adma Biologics, Inc. (ADMA) Q1 2022 Earnings Call Transcript
Revenue
$29.10M
▲ 81.3% YoY
Diluted EPS
$-0.13
Gross margin
12.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-19
Adma Biologics, Inc. (ADMA) Q4 2021 Earnings Call Transcript
Revenue
$26.38M*
▲ 89% YoY
Gross margin
13.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-20
Adma Biologics, Inc. (ADMA) Q3 2021 Earnings Call Transcript
Revenue
$20.68M
▲ 101.2% YoY
Diluted EPS
$-0.13
Gross margin
1.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Adma Biologics, Inc. (ADMA) Q2 2021 Earnings Call Transcript
Revenue
$17.83M
▲ 129% YoY
Diluted EPS
$-0.15
Gross margin
-5.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Adma Biologics, Inc. (ADMA) Q1 2021 Earnings Call Transcript
Revenue
$16.05M
▲ 57.3% YoY
Diluted EPS
$-0.16
Gross margin
-10.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Adma Biologics, Inc. (ADMA) Q4 2020 Earnings Call Transcript
Revenue
$13.96M*
▲ 15.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Adma Biologics, Inc. (ADMA) Q3 2020 Earnings Call Transcript
Revenue
$10.28M
▲ 42.3% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Adma Biologics, Inc. (ADMA) Q2 2020 Earnings Call Transcript
Revenue
$7.79M
▲ 18.7% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Adma Biologics, Inc. (ADMA) Q1 2020 Earnings Call Transcript
Revenue
$10.20M
▲ 189.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-13
Adma Biologics, Inc. (ADMA) Q4 2019 Earnings Call
Revenue
$12.04M*
▲ 196.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 1368514 CUSIP 000899104 13F (30d) 10 filings 7 filers Visit website Investor relations